is there a patent on semaglutide Novo Nordisk to lose blockbuster drug over small fee 'Indian Discount': Why Semaglutide is

Our findings are suggestive that an increased BMI is associated with significantly larger MI risk reduction with GLP-1RA

Glucagon-like peptide 1 (GLP-1) acts as an incretin hormone and anorexigenic neuropeptide, prompting the successful and ongoing development of GLP-1-based therapies for type 2 diabetes and obesity 1,2

In other words, the idea that eating meat increases the risk of heart disease in all people under all circumstances is an unlikely hypothesis

Long-term studies show promising results

n = 6 per group

Semaglutide (Wegovy) GLP-1 Receptor Agonist Administration : Once-weekly subcutaneous injection OR once-daily oral tablet